Publications
Detailed Information
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Ahn, Joong Bae | - |
dc.contributor.author | Shin, Sang Jun | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Oh, Do Youn | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Kim, Tae Won | - |
dc.contributor.author | Lee, Namsu | - |
dc.contributor.author | Byun, Jae Ho | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Park, Joon Oh | - |
dc.contributor.author | Park, Se Hoon | - |
dc.contributor.author | Lim, Ho Yeong | - |
dc.contributor.author | Kang, Won Ki | - |
dc.date.accessioned | 2012-05-24T02:09:37Z | - |
dc.date.available | 2012-05-24T02:09:37Z | - |
dc.date.created | 2021-11-23 | - |
dc.date.created | 2021-11-23 | - |
dc.date.issued | 2009-09 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, Vol.64 No.4, pp.657-663 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.other | 148337 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76385 | - |
dc.description.abstract | Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, anti-angiogenesis, and apoptosis. This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients. Patients received irinotecan 180 mg/m(2) as a 90-min infusion followed by leucovorin 200 mg/m(2) in a 2-h infusion, and then 5-FU 400 mg/m(2) bolus injection followed by 2,400 mg/m(2) as a 46-h continuous infusion. Treatment cycles were repeated every 2 weeks until documented disease progression, unacceptable toxicity, or patient's refusal. Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest. From October 2005 to June 2006, 49 patients were enrolled. The overall response rate (ORR) was 46.9% (95% CI, 31.0-58.8) by intent-to-treat analysis and 45.8% (95% CI, 33.3-62.8) by per-protocol analysis. There were one complete response (CR) and 22 partial responses (PRs). Both CR and PRs were confirmed at least 4 weeks later. The disease-control rate was 83.7% (95% CI, 73.4-94.0). The median follow-up duration was 25.6 months (range, 20.9-28.8 months). The median survival of all patients was 21.8 months (95% CI, 14.4, 29.2). The median TTP was 9.9 months (95% CI, 6.4, 13.3). No patients experienced additional adverse effect that was definitely caused by simvastatin drug therapy in this trial. The combination of simvastatin plus FOLFIRI was a feasible regimen with promising antitumor activity. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | Springer Verlag | - |
dc.title | Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s00280-008-0913-5 | - |
dc.citation.journaltitle | Cancer Chemotherapy and Pharmacology | - |
dc.description.citedreference | Karapetis CS, 2008, NEW ENGL J MED, V359, P1757 | - |
dc.description.citedreference | Xiao H, 2008, INT J CANCER, V123, P983, DOI 10.1002/ijc.23718 | - |
dc.description.citedreference | Vinogradova Y, 2007, GASTROENTEROLOGY, V133, P393, DOI 10.1053/j.gastro.2007.05.023 | - |
dc.description.citedreference | Setoguchi S, 2007, CIRCULATION, V115, P27, DOI 10.1161/CIRCULATIONAHA.106.650176 | - |
dc.description.citedreference | Lee J, 2006, BIOCHEM BIOPH RES CO, V339, P748, DOI 10.1016/j.bbrc.2005.11.075 | - |
dc.description.citedreference | Dulak J, 2005, CURR CANCER DRUG TAR, V5, P579 | - |
dc.description.citedreference | Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113 | - |
dc.description.citedreference | Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792 | - |
dc.description.citedreference | Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010 | - |
dc.description.citedreference | Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027 | - |
dc.description.citedreference | Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113 | - |
dc.description.citedreference | NUBEL T, 2004, FASEB J, V18, P140 | - |
dc.description.citedreference | Seeger H, 2003, EXP CLIN ENDOCR DIAB, V111, P47 | - |
dc.description.citedreference | Chan KKW, 2003, CLIN CANCER RES, V9, P10 | - |
dc.description.citedreference | Alber HF, 2002, J AM COLL CARDIOL, V39, P1951 | - |
dc.description.citedreference | Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P505 | - |
dc.description.citedreference | Belgore FM, 2001, AM J CARDIOL, V87, P805 | - |
dc.description.citedreference | Kim WS, 2001, INVEST NEW DRUG, V19, P81 | - |
dc.description.citedreference | BELGORE FM, 2001, AM J CARDIOL, V87, pA9 | - |
dc.description.citedreference | Bouterfa HL, 2000, ANTICANCER RES, V20, P2761 | - |
dc.description.citedreference | Douillard JY, 2000, LANCET, V355, P1041 | - |
dc.description.citedreference | Therasse P, 2000, J NATL CANCER I, V92, P205 | - |
dc.description.citedreference | Agarwal B, 1999, CLIN CANCER RES, V5, P2223 | - |
dc.description.citedreference | Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579 | - |
dc.description.citedreference | Iyer L, 1998, J CLIN INVEST, V101, P847 | - |
dc.description.citedreference | Rando RR, 1996, BIOCHEM SOC T, V24, P682 | - |
dc.description.citedreference | Thibault A, 1996, CLIN CANCER RES, V2, P483 | - |
dc.description.citedreference | CASEY PJ, 1995, SCIENCE, V268, P221 | - |
dc.description.citedreference | SUMI S, 1994, PANCREAS, V9, P657 | - |
dc.description.citedreference | JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628 | - |
dc.description.citedreference | PAN HY, 1990, J CLIN PHARMACOL, V30, P1128 | - |
dc.description.citedreference | GOLDSTEIN JL, 1990, NATURE, V343, P425 | - |
dc.description.citedreference | BOS JL, 1989, CANCER RES, V49, P4682 | - |
dc.description.citedreference | SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1 | - |
dc.description.citedreference | KORNBRUST DJ, 1989, J PHARMACOL EXP THER, V248, P498 | - |
dc.description.tc | 16 | - |
dc.identifier.wosid | 000268479700002 | - |
dc.identifier.scopusid | 2-s2.0-68149131593 | - |
dc.citation.endpage | 663 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 657 | - |
dc.citation.volume | 64 | - |
dc.identifier.sci | 000268479700002 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Oh, Do Youn | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | CANCER CELLS | - |
dc.subject.keywordPlus | MEVALONATE PATHWAY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | LOVASTATIN | - |
dc.subject.keywordPlus | STATINS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | GLUCURONIDATION | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | INHIBITORS | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.